Guillermo Ruiz-Irastorza

Summary

Affiliation: Hospital de Cruces
Country: Spain

Publications

  1. doi [The antiphospholipid syndrome in the 21st century]
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, Barakaldo, Bizkaia, Espana
    Med Clin (Barc) 133:390-6. 2009
  2. doi Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, Barakaldo, Spain
    Arthritis Care Res (Hoboken) 62:1160-5. 2010
  3. ncbi Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus
    G Ruiz-Irastorza
    Service and Department of Internal Medicine, Hospital de Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain
    Lupus 13:900-5. 2004
  4. ncbi Stroke and antiphospholipid syndrome: the treatment debate
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, 48903 Bizkaia, Spain
    Rheumatology (Oxford) 44:971-4. 2005
  5. ncbi High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus
    Guillermo Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Bizkaia, Spain
    Arch Intern Med 164:77-82. 2004
  6. ncbi Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
    G Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
    Lupus 15:577-83. 2006
  7. pmc Antimalarials may influence the risk of malignancy in systemic lupus erythematosus
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, 48903 Bizkaia, Spain
    Ann Rheum Dis 66:815-7. 2007
  8. doi Antiphospholipid syndrome
    Guillermo Ruiz-Irastorza
    Service of Internal Medicine, Hospital de Cruces University of the Basque Country, Bizkaia, Spain
    Lancet 376:1498-509. 2010
  9. ncbi A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, and University of the Basque Country, Bizkaia, Spain
    Arthritis Rheum 57:1487-95. 2007
  10. doi Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, 48903 Bizkaia, Spain
    Rheumatology (Oxford) 47:920-3. 2008

Collaborators

  • Munther A Khamashta
  • Gerard Espinosa
  • Mary Carmen Amigo
  • Beverley J Hunt
  • José Gabriel Erdozain
  • Ioana Ruiz-Arruza
  • Alvaro Danza
  • Irama Villar
  • Cristina Gonzalez-Echavarri
  • Amaia Ugarte
  • Florencia Vivero
  • Javier Nieto
  • Eguzkine Ochoa
  • Iñigo Les
  • Agustin Martinez-Berriotxoa
  • Beatriz Ruiz-Estevez
  • Irene Maderuelo
  • Cristiana Barbosa
  • Rosa Larrieta
  • Iván Cabezas-Rodríguez
  • Jose Alejandro Medina
  • Miguel Angel Moran
  • Ana M Zubiaga
  • Mikel Iriondo
  • Andone Estonba
  • Ana Bielsa
  • Jose Luis Pomar
  • Maria Isabel Segura
  • Oier Ateka-Barrutia
  • Ignacio Pérez-Valero
  • Maider Garmendia
  • Maria Victoria Egurbide
  • Jose Gabriel Erdozain
  • Ciriaco Aguirre

Detail Information

Publications34

  1. doi [The antiphospholipid syndrome in the 21st century]
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, Barakaldo, Bizkaia, Espana
    Med Clin (Barc) 133:390-6. 2009
    ..Low dose aspirin should be given to every pregnant woman with antiphospholipid antibodies, with the addition of low molecular weight heparin in those with previous thrombosis, previous fetal death or failure of monotherapy with aspirin...
  2. doi Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, Barakaldo, Spain
    Arthritis Care Res (Hoboken) 62:1160-5. 2010
    ..To analyze whether changes in serum 25-hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE)...
  3. ncbi Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus
    G Ruiz-Irastorza
    Service and Department of Internal Medicine, Hospital de Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain
    Lupus 13:900-5. 2004
    ..11-10.03) and increasing damage since diagnosis (OR 2.46, 95% CI 1.24-4.87). No autoantibody was a predictor of the outcome 'SDI > or = 1 or death at five years'. The conclusion was that aPL predict early damage in patients with SLE...
  4. ncbi Stroke and antiphospholipid syndrome: the treatment debate
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, 48903 Bizkaia, Spain
    Rheumatology (Oxford) 44:971-4. 2005
    ..Due to the often devastating consequences of stroke, we believe there is a place for prolonged, high-intensity anticoagulation in patients with APS and cerebral arterial thrombosis...
  5. ncbi High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus
    Guillermo Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Bizkaia, Spain
    Arch Intern Med 164:77-82. 2004
    ..Whether antiphospholipid syndrome (APS) is the cause of increased irreversible organ damage and mortality in lupus patients is not well established...
  6. ncbi Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
    G Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
    Lupus 15:577-83. 2006
    ..14 (95% CI 0.04-0.48). Our study shows a protective effect of antimalarials against thrombosis and an increased survival of SLE patients taking these drugs. These data support the routine use of antimalarials in all patients with SLE...
  7. pmc Antimalarials may influence the risk of malignancy in systemic lupus erythematosus
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, 48903 Bizkaia, Spain
    Ann Rheum Dis 66:815-7. 2007
    ..Recent studies suggest that antimalarials have antineoplastic properties...
  8. doi Antiphospholipid syndrome
    Guillermo Ruiz-Irastorza
    Service of Internal Medicine, Hospital de Cruces University of the Basque Country, Bizkaia, Spain
    Lancet 376:1498-509. 2010
    ..Hydroxychloroquine is a potential additional treatment for this syndrome. Possible future therapies for non-pregnant patients with antiphospholipid syndrome are statins, rituximab, and new anticoagulant drugs...
  9. ncbi A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, and University of the Basque Country, Bizkaia, Spain
    Arthritis Rheum 57:1487-95. 2007
    ..To systematically review the efficacy and safety data of different therapeutic approaches in patients with antiphospholipid antibodies (aPL) and thrombosis...
  10. doi Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, 48903 Bizkaia, Spain
    Rheumatology (Oxford) 47:920-3. 2008
    ..We aimed to establish the prevalence, predictors and clinical consequences of vitamin D deficiency in patients with SLE...
  11. doi Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, University of the Basque Country, 48903 Bizkaia, Spain
    Ann Rheum Dis 69:20-8. 2010
    ..The aim of the present work was to analyse all the published evidence of the beneficial and adverse effects of AM therapy in systemic lupus erythematosus (SLE)...
  12. pmc Predictors of major infections in systemic lupus erythematosus
    Guillermo Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Pza Cruces s n, Barakaldo, Bizkaia, Spain
    Arthritis Res Ther 11:R109. 2009
    ..Infections commonly complicate the course of systemic lupus erythematosus (SLE). Our aim is to investigate the clinical predictors of major infections in patients with SLE...
  13. ncbi Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus
    Agustin Martinez-Berriotxoa
    Service of Internal Medicine, Hospital de Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain
    Lupus 16:810-6. 2007
    ..Risk of thrombosis is not increased in SLE patients with negative LA and transiently positive aCL, even fulfilling Sapporo laboratory criteria, when compared with aPL-negative SLE patients...
  14. doi Lupus and pregnancy: integrating clues from the bench and bedside
    Guillermo Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
    Eur J Clin Invest 41:672-8. 2011
    ..Postpartum follow-up is important...
  15. ncbi Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus
    Guillermo Ruiz-Irastorza
    Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Bizkaia, Spain
    Clin Exp Rheumatol 34:466-72. 2016
    ..We aimed to analyse drug therapy during the first year of follow-up according to disease severity...
  16. doi [Treatment of systemic lupus erythematosus: myths, certainties and doubts]
    Guillermo Ruiz-Irastorza
    Unidad de Investigación de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Universitario Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Barakaldo, Bizkaia, España Electronic address
    Med Clin (Barc) 141:533-42. 2013
    ..Hydroxichloroquine improves survival, decreases the risk of thrombosis and flares and is safe in pregnancy, and should be considered the baseline therapy in most SLE patients. ..
  17. doi Prednisone in lupus nephritis: how much is enough?
    Guillermo Ruiz-Irastorza
    Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, Spain University of the Basque Country, Bizkaia, The Basque Country, Spain Electronic address
    Autoimmun Rev 13:206-14. 2014
    ..To assess the effectiveness and safety of a protocol using medium doses of prednisone to treat lupus nephritis...
  18. ncbi Antiphospholipid syndrome in pregnancy
    Guillermo Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, 48903 Bizkaia, Spain
    Rheum Dis Clin North Am 33:287-97, vi. 2007
    ..Doppler studies of the umbilical and uterine arteries play an important role in predicting APS-related complications during pregnancy...
  19. doi Intensity and duration of anticoagulation therapy in antiphospholipid syndrome
    Iñigo Les
    Autoimmune Diseases Research Unit, Service of Internal Medicine, Hospital Universitario Cruces, Bizkaia, Spain
    Semin Thromb Hemost 38:339-47. 2012
    ..Nevertheless, anticoagulation regimes of shorter duration could be given in selected patients with venous thromboembolism who have transient risk factors and a low-risk profile...
  20. doi Managing lupus patients during pregnancy
    Guillermo Ruiz-Irastorza
    Service and Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
    Best Pract Res Clin Rheumatol 23:575-82. 2009
    ..Post-partum follow-up is also essential...
  21. pmc Predictors of peripheral arterial disease in SLE change with patient's age
    José Gabriel Erdozain
    Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Bizkaia, The Basque Country, Spain
    Lupus Sci Med 4:e000190. 2017
    ..To analyse the differential influence of risk factors of peripheral artery disease (PAD) according to age in patients with SLE...
  22. ncbi The treatment of antiphospholipid syndrome: a harmonic contrast
    Guillermo Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, 48903 Barakaldo, Bizkaia, Spain
    Best Pract Res Clin Rheumatol 21:1079-92. 2007
    ..Correction of vascular risk factors and a high-risk management of pregnancy, including Doppler studies of the uterine and umbilical vessels, are warranted. Hydroxychloroquine and statins are likely to become important in the future...
  23. doi Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy
    Guillermo Ruiz-Irastorza
    Autoimmune Diseases Research Unit, Department of Internal Medicine, Hospital Universitario Cruces, University of the Basque Country, UPV EHU, Bizkaia, Spain
    Autoimmun Rev 12:410-5. 2013
    ..To investigate the prevalence and predictors of pulmonary hypertension (PH) in patients with systemic lupus erythematosus (SLE) and to validate a diagnostic strategy...
  24. doi Glucocorticoid use and abuse in SLE
    Guillermo Ruiz-Irastorza
    Servicio de Medicina Interna Hospital de Cruces, 48903 Bizkaia, Spain
    Rheumatology (Oxford) 51:1145-53. 2012
    ..5 mg of prednisone seem to minimize adverse effects. Combination therapy with HCQ and the judicious use of immunosuppressive drugs help to keep prednisone therapy within those limits...
  25. ncbi Management of thrombosis in antiphospholipid syndrome and systemic lupus erythematosus in pregnancy
    Guillermo Ruiz-Irastorza
    Service and Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
    Ann N Y Acad Sci 1051:606-12. 2005
    ..Peripartum thromboprophylaxis with LMWH in women receiving aspirin-only regimens and prevention of osteoporosis in those treated with heparin are considered essential in the medical management of these patients...
  26. doi [Pregnancy in systemic autoimmune diseases: Myths, certainties and doubts]
    Alvaro Danza
    Unidad Docente Asistencial en Enfermedades Autoinmunes Sistémicas y Reumatológicas, Clinica Medica, Hospital Pasteur, Departamento de Medicina, Facultad de Medicina, Universidad de la Republica, Administración de Servicios de Salud del Estado ASSE, Montevideo, Uruguay Unidad de Investigación de Enfermedades Autoinmunes, Servicio de Medicina Interna, BioCruces Health Research Institute, Hospital Universitario Cruces, Universidad del País Vasco UPV Euskal Herriko Unibertsitatea EHU, Barakaldo, Vizcaya, España Electronic address
    Med Clin (Barc) 147:306-12. 2016
    ..Monitoring requires a multidisciplinary team, serial analytic controls and Doppler ultrasound of maternal and fetal circulation. Evaluation of the activity of the disease is essential. ..
  27. doi Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis
    Ioana Ruiz-Arruza
    Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Bizkaia, The Basque Country, Spain
    Autoimmun Rev 14:875-9. 2015
    ..To compare the efficacy and safety of high vs. low-moderate oral doses of prednisone to treat patients with highly active lupus at diagnosis...
  28. doi Prevalence and significance of persistently positive antiphospholipid antibodies in women with preeclampsia
    Cristina Gonzalez-Echavarri
    From the Autoimmune Diseases Research Unit, Department of Internal Medicine, and the Department of Obstetrics, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Universidad del País Vasco UPV Euskal Herriko Unibertsitatea EHU, Bizkaia, Spain C Gonzalez Echavarri, MD, Senior Registrar I Villar, MD, Consultant Physician A Ugarte, MD, Consultant Physician G Ruiz Irastorza, MD, PhD, Professor of Medicine, Head of the Autoimmune Diseases Research Unit, Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, UPV EHU R Larrieta, MD, Consultant Physician, Department of Obstetrics, BioCruces Health Research Institute, Hospital Universitario Cruces
    J Rheumatol 42:210-3. 2015
    ..To determine the prevalence of antiphospholipid antibodies (aPL) and their association with obstetric outcomes in women with preeclampsia...
  29. doi Peripheral arterial disease in systemic lupus erythematosus: prevalence and risk factors
    José Gabriel Erdozain
    From the Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Bizkaia Department of Internal Medicine, Hospital de Mendaro, Gipuzkoa, The Basque Country, Spain
    J Rheumatol 41:310-7. 2014
    ..To analyze the prevalence of peripheral arterial disease (PAD) and cardiovascular (CV) risk factors in a cohort of patients with systemic lupus erythematosus (SLE) and to identify variables potentially related to PAD...
  30. doi Cardiac valve replacement in patients with antiphospholipid syndrome
    José Gabriel Erdozain
    Hospital Universitario Cruces, Barakaldo, Spain
    Arthritis Care Res (Hoboken) 64:1256-60. 2012
    ..To analyze the results of cardiac valve replacement in a multicenter cohort of patients with antiphospholipid syndrome (APS) and to identify prognostic factors of poor outcome...
  31. doi Antiphospohlipid syndrome in obstetrics
    Alvaro Danza
    Autoimmune Diseases Research Unit, Department of Internal Medicine, Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain
    Best Pract Res Clin Obstet Gynaecol 26:65-76. 2012
    ..Close blood pressure control and early detection of proteinuria, together with Doppler studies of the utero-placental circulation should be included in the management protocol...
  32. doi Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus
    Florencia Vivero
    Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Bizkaia, The Basque Country, Spain Autoimmune Diseases Unit, Hospital Privado de Comunidad, Mar del Plata, Argentina
    Autoimmun Rev 15:1134-1140. 2016
    ..We aimed to study the frequency, severity and predictors of valvular heart disease (VHD) in our lupus cohort...
  33. doi Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus
    Ioana Ruiz-Arruza
    Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Bizkaia, The Basque Country, Spain
    Rheumatology (Oxford) 53:1470-6. 2014
    ..The aim of this study was to analyse the relationship between glucocorticoids and damage accrual in SLE...
  34. pmc Thrombotic antiphospholipid syndrome shows strong haplotypic association with SH2B3-ATXN2 locus
    Eguzkine Ochoa
    Department of Genetics, Physical Anthropology and Animal Physiology School of Science and Technology, University of the Basque Country, UPV EHU, Leioa, Spain
    PLoS ONE 8:e67897. 2013
    ..Little is known about the genetic risk factors involved in thrombosis development among aPLA carriers...